Pfizer and BioNTech Coronavirus Vaccine Accepted for Rolling Review in Canada
The coronavirus vaccine candidate being developed by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) is now undergoing its first regulatory review in North America. The two companies announced that their BNT162b2 has been accepted for a rolling review by Health Canada, that country's healthcare regulatory authority.
A rolling review is one undertaken while a candidate is still in development; this is done in cases of urgent need, as with the current global pandemic.
Image source: Getty Images.
Source Fool.com